First National Bank of Omaha Acquires 8,026 Shares of Merck & Co., Inc. $MRK

Key Points

• First National Bank of Omaha increased its Merck stake by 7% in the second quarter, adding 8,026 shares to own 123,043 shares valued at approximately $15.9 million. Institutional investors collectively own 76.07% of Merck.
• Analyst sentiment is broadly positive: 15 analysts rate Merck a Buy and eight rate it a Hold, producing a “Moderate Buy” consensus and an average price target of $147.60. Recent targets from UBS and BMO rose to $175 and $170, respectively.
• Merck’s outlook is supported by positive melanoma trial results and upcoming pipeline catalysts, but insider selling, elevated valuation and uncertainty around the cancer-vaccine opportunity present risks. The company also declared a quarterly dividend of $0.85 per share, equivalent to a 2.2% annualized yield.

First National Bank of Omaha boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 7.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,043 shares of the company's stock after purchasing an additional 8,026 shares during the period. First National Bank of Omaha's holdings in Merck & Co., Inc. were worth $15,876,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. increased its stake in shares of Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock valued at $29,169,479,000 after buying an additional 1,073,507 shares in the last quarter. State Street Corp lifted its position in Merck & Co., Inc. by 1.6% during the 4th quarter. State Street Corp now owns 120,040,168 shares of the company's stock worth $12,737,504,000 after buying an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the last quarter. Geode Capital Management LLC grew its holdings in Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after acquiring an additional 249,110 shares during the last quarter. Finally, Morgan Stanley increased its position in Merck & Co., Inc. by 0.8% in the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company's stock valued at $4,731,018,000 after acquiring an additional 359,486 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Analysts Set New Price Targets

MRK has been the subject of a number of research analyst reports. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 target price for the company. Guggenheim increased their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a report on Saturday, August 22nd. BMO Capital Markets boosted their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a research report on Thursday, August 20th. Finally, UBS Group upped their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $147.60.

Insider Activity at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the sale, the executive vice president directly owned 110,167 shares of the company's stock, valued at $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David R. Maraldo sold 18,706 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company's stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $153.21 on Thursday. The company has a market cap of $378.00 billion, a PE ratio of 122.57, a PEG ratio of 6.56 and a beta of 0.19. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $156.92. The company's 50-day moving average is $130.39 and its two-hundred day moving average is $122.04.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.'s revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is currently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source